Skip to main content
Top
Published in: Diagnostic Pathology 1/2014

Open Access 01-12-2014 | Research

Berberine inhibits the expression of hypoxia induction factor-1alpha and increases the radiosensitivity of prostate cancer

Authors: Qu Zhang, Chi Zhang, Xi Yang, Baixia Yang, Jinfeng Wang, Yahui Kang, Zhongming Wang, Defan Li, Guanhong Huang, Zhaoming Ma, Xinchen Sun, Jing Cai, Guangzhou Tao, Shengbin Dai, Weidong Mao, Jianxin Ma

Published in: Diagnostic Pathology | Issue 1/2014

Login to get access

Abstract

Background

The radiation resistance of prostate cancer remains the primary obstacle to improve patient survival. This study aimed to investigate the effects of berberine, a commonly used natural product, on the radiosensitivity of prostate cancer.

Methods

Prostate cancer cell line LNCaP and DU-145 were subjected to hypoxia and/or ionizing radiation (IR), in the presence or absence of berberine treatment. Cell growth and colony formation, and apoptosis were evaluated. Moreover, LNCaP cells were xenografted into nude mice and subjected to IR and/or berberine treatment. The expression of HIF-1α and VEGF in prostate cancer cells and xenografts was detected by Western blot analysis.

Results

Berberine increased radiosensitivity of prostate cancer cells and xenografts in a dose dependent manner, and this was correlated with the inhibition of HIF-1α and VEGF expression.

Conclusions

Berberine may inhibit the expression of HIF-1α and VEGF and thus confer radiosensitivity on prostatic cancer cells. Berberine has potential application as an adjuvant in radiotherapy of prostatic cancer.

Virtual Slides

The virtual slide(s) for this article can be found here: http://​www.​diagnosticpathol​ogy.​diagnomx.​eu/​vs/​1519827543125021​.
Appendix
Available only for authorised users
Literature
1.
go back to reference Wang H, Yao Y, Li B: Factors associated with the survival of prostate cancer patients with rectal involvement. Diagn Pathol. 2014, 9: 35-10.1186/1746-1596-9-35.PubMedPubMedCentralCrossRef Wang H, Yao Y, Li B: Factors associated with the survival of prostate cancer patients with rectal involvement. Diagn Pathol. 2014, 9: 35-10.1186/1746-1596-9-35.PubMedPubMedCentralCrossRef
2.
go back to reference Marcos-Gragera R, Salmerón D, Izarzugaza I, Ardanaz E, Serdà BC, Larrañaga N, San Román E, Navarro C, Chirlaque MD: Trends in prostate cancer survival in Spain: results from population-based cancer registries. Clin Transl Oncol. 2012, 14: 458-64. 10.1007/s12094-012-0824-0.PubMedCrossRef Marcos-Gragera R, Salmerón D, Izarzugaza I, Ardanaz E, Serdà BC, Larrañaga N, San Román E, Navarro C, Chirlaque MD: Trends in prostate cancer survival in Spain: results from population-based cancer registries. Clin Transl Oncol. 2012, 14: 458-64. 10.1007/s12094-012-0824-0.PubMedCrossRef
3.
go back to reference Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T, Tabata Y, Rosser CJ, Uemura H, Hirao Y: Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther. 2008, 7: 1864-1870. 10.1158/1535-7163.MCT-07-2198.PubMedCrossRef Tomioka A, Tanaka M, De Velasco MA, Anai S, Takada S, Kushibiki T, Tabata Y, Rosser CJ, Uemura H, Hirao Y: Delivery of PTEN via a novel gene microcapsule sensitizes prostate cancer cells to irradiation. Mol Cancer Ther. 2008, 7: 1864-1870. 10.1158/1535-7163.MCT-07-2198.PubMedCrossRef
4.
go back to reference Jiang XD, Qiao Y, Dai P, Wu J, Song DA, Li SQ, Fan YW: Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC. Clin Transl Oncol. 2012, 14: 465-70. 10.1007/s12094-012-0825-z.PubMedCrossRef Jiang XD, Qiao Y, Dai P, Wu J, Song DA, Li SQ, Fan YW: Preliminary clinical study of weekly recombinant human endostatin as a hypoxic tumour cell radiosensitiser combined with radiotherapy in the treatment of NSCLC. Clin Transl Oncol. 2012, 14: 465-70. 10.1007/s12094-012-0825-z.PubMedCrossRef
5.
go back to reference Ikeda E: Cellular response to tissue hypoxia and its involvement in disease progression. Pathol Int. 2005, 55: 603-610. 10.1111/j.1440-1827.2005.01877.x.PubMedCrossRef Ikeda E: Cellular response to tissue hypoxia and its involvement in disease progression. Pathol Int. 2005, 55: 603-610. 10.1111/j.1440-1827.2005.01877.x.PubMedCrossRef
6.
go back to reference Chi KH, Wang YS, Kao SJ: Improving radioresponse through modification of the tumor immunological microenvironment. Cancer Biother Radiopharm. 2012, 27: 6-10.1089/cbr.2011.1048.PubMedCrossRef Chi KH, Wang YS, Kao SJ: Improving radioresponse through modification of the tumor immunological microenvironment. Cancer Biother Radiopharm. 2012, 27: 6-10.1089/cbr.2011.1048.PubMedCrossRef
7.
go back to reference Ishizaki F, Hara N, Koike H, Kawaguchi M, Tadokoro A, Takizawa I, Nishiyama T, Takahashi K, Hohenfellner R: Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study. Diagn Pathol. 2012, 7: 68-10.1186/1746-1596-7-68.PubMedPubMedCentralCrossRef Ishizaki F, Hara N, Koike H, Kawaguchi M, Tadokoro A, Takizawa I, Nishiyama T, Takahashi K, Hohenfellner R: Prediction of pathological and oncological outcomes based on extended prostate biopsy results in patients with prostate cancer receiving radical prostatectomy: a single institution study. Diagn Pathol. 2012, 7: 68-10.1186/1746-1596-7-68.PubMedPubMedCentralCrossRef
8.
go back to reference Tian Y, Zhao L, Zhang H, Liu X, Zhao L, Zhao X, Li Y, Li J: AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. Diagn Pathol. 2014, 9: 42-10.1186/1746-1596-9-42.PubMedPubMedCentralCrossRef Tian Y, Zhao L, Zhang H, Liu X, Zhao L, Zhao X, Li Y, Li J: AKR1C3 overexpression may serve as a promising biomarker for prostate cancer progression. Diagn Pathol. 2014, 9: 42-10.1186/1746-1596-9-42.PubMedPubMedCentralCrossRef
9.
go back to reference Ma L, Zhao J, Li T, He Y, Wang J, Xie L, Qin X, Li S: Association between tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol. 2014, 9: 74-10.1186/1746-1596-9-74.PubMedPubMedCentralCrossRef Ma L, Zhao J, Li T, He Y, Wang J, Xie L, Qin X, Li S: Association between tumor necrosis factor-alpha gene polymorphisms and prostate cancer risk: a meta-analysis. Diagn Pathol. 2014, 9: 74-10.1186/1746-1596-9-74.PubMedPubMedCentralCrossRef
10.
go back to reference Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME: Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res. 2002, 8: 3276-3284.PubMed Zellweger T, Chi K, Miyake H, Adomat H, Kiyama S, Skov K, Gleave ME: Enhanced radiation sensitivity in prostate cancer by inhibition of the cell survival protein clusterin. Clin Cancer Res. 2002, 8: 3276-3284.PubMed
11.
go back to reference Chiu HW, Chen YA, Ho SY, Wang YJ: Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells. PLoS One. 2012, 7: e31579-10.1371/journal.pone.0031579.PubMedPubMedCentralCrossRef Chiu HW, Chen YA, Ho SY, Wang YJ: Arsenic trioxide enhances the radiation sensitivity of androgen-dependent and -independent human prostate cancer cells. PLoS One. 2012, 7: e31579-10.1371/journal.pone.0031579.PubMedPubMedCentralCrossRef
12.
go back to reference Teicher BA: Hypoxia and drug resistance. Cancer Metastasis Rev. 1994, 13: 139-168. 10.1007/BF00689633.PubMedCrossRef Teicher BA: Hypoxia and drug resistance. Cancer Metastasis Rev. 1994, 13: 139-168. 10.1007/BF00689633.PubMedCrossRef
13.
go back to reference Harada H, Itasaka S, Zhu Y, Zeng L, Xie X, Morinibu A, Shinomiya K, Hiraoka M: Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer. 2009, 100: 747-757. 10.1038/sj.bjc.6604939.PubMedPubMedCentralCrossRef Harada H, Itasaka S, Zhu Y, Zeng L, Xie X, Morinibu A, Shinomiya K, Hiraoka M: Treatment regimen determines whether an HIF-1 inhibitor enhances or inhibits the effect of radiation therapy. Br J Cancer. 2009, 100: 747-757. 10.1038/sj.bjc.6604939.PubMedPubMedCentralCrossRef
14.
go back to reference Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao C, Feng S, Guo H, Xu B, Yang Q, Gong Y, Shao C: Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS One. 2011, 6: 23427-10.1371/journal.pone.0023427.CrossRef Liu Q, Jiang H, Liu Z, Wang Y, Zhao M, Hao C, Feng S, Guo H, Xu B, Yang Q, Gong Y, Shao C: Berberine radiosensitizes human esophageal cancer cells by downregulating homologous recombination repair protein RAD51. PLoS One. 2011, 6: 23427-10.1371/journal.pone.0023427.CrossRef
15.
go back to reference Orr WS, Denbo JW, Saab KR, Ng CY, Wu J, Li K, Garner JM, Morton CL, Du Z, Pfeffer LM, Davidoff AM: Curcumin potentiates rhabdomyosarcoma radiosensitivity by suppressing NF-kB activity. PLoS One. 2013, 8: 51309-10.1371/journal.pone.0051309.CrossRef Orr WS, Denbo JW, Saab KR, Ng CY, Wu J, Li K, Garner JM, Morton CL, Du Z, Pfeffer LM, Davidoff AM: Curcumin potentiates rhabdomyosarcoma radiosensitivity by suppressing NF-kB activity. PLoS One. 2013, 8: 51309-10.1371/journal.pone.0051309.CrossRef
16.
go back to reference Peng PL, Kuo WH, Tseng HC, Chou FP: Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. Int J Radiat Oncol Biol Phys. 2008, 70: 529-542. 10.1016/j.ijrobp.2007.08.034.PubMedCrossRef Peng PL, Kuo WH, Tseng HC, Chou FP: Synergistic tumor-killing effect of radiation and berberine combined treatment in lung cancer: the contribution of autophagic cell death. Int J Radiat Oncol Biol Phys. 2008, 70: 529-542. 10.1016/j.ijrobp.2007.08.034.PubMedCrossRef
Metadata
Title
Berberine inhibits the expression of hypoxia induction factor-1alpha and increases the radiosensitivity of prostate cancer
Authors
Qu Zhang
Chi Zhang
Xi Yang
Baixia Yang
Jinfeng Wang
Yahui Kang
Zhongming Wang
Defan Li
Guanhong Huang
Zhaoming Ma
Xinchen Sun
Jing Cai
Guangzhou Tao
Shengbin Dai
Weidong Mao
Jianxin Ma
Publication date
01-12-2014
Publisher
BioMed Central
Published in
Diagnostic Pathology / Issue 1/2014
Electronic ISSN: 1746-1596
DOI
https://doi.org/10.1186/1746-1596-9-98

Other articles of this Issue 1/2014

Diagnostic Pathology 1/2014 Go to the issue